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Abstract:
Background: Clinical use of biosimilar infliximab (CT-P13) in inflammatory bowel
diseases (IBDs) is based on extrapolation of indication from clinical studies performed
in rheumatological diseases. Only few data exist of behaviour of infliximab trough
levels (TLs) and anti-drug antibodies (ADAs) during switching.
Aim: The objective of this study was to evaluate changes in TLs, ADA formation and
disease activity after switching from originator infliximab to biosimilar one.
Methods: All our IBD patients receiving maintenance infliximab therapy were
switched to biosimilar infliximab. TLs and ADAs were measured before the last
originator infusion and before the third biosimilar infusion. Laboratory values, disease
activity indices (Partial Mayo Score and Harvey-Bradshaw Index) and demographic
data were collected from patient records.
Results: A total of 62 patients were included in the final analysis (32 Crohn’s disease,
30 ulcerative colitis (UC) or IBD-unclassified). No significant changes in median TLs
before (5.5mg/l) and after switching (5.5mg/l, p=0.05) occurred in the entire study
group or in the Crohn’s disease subgroup (5.75mg/l and 6.5 mg/l, p=0.68). However, in
the subgroup of ulcerative colitis, the change in median TL was significantly different
(from 5.2 to 4.25 mg/l, p=0.019). Two patients developed ADAs after switching. No
changes in disease activity were detected during switching and no safety concerns
occurred.
Conclusions: Switching from originator to biosimilar infliximab resulted in statistically
significant differences in infliximab TLs in patients with UC but not in patients with
3Crohn’s disease. The clinical significance for this difference is doubtful and in neither
group changes in disease activity occurred.
Keywords : infliximab, biosimilar, CT-P13, Crohn´s disease, ulcerative colitis, trough
levels, TNF-α antagonist.
41. Introduction
The use of chimeric monoclonal antibody (IgG1) infliximab (IFX) against TNF-a has emerged
since the FDA approval in 1998 for the treatment of Crohn´s disease (CD) and in 2005 for
ulcerative colitis (UC) [1]. IFX is effective in both children and adults with moderate to severe
CD and UC in inducing and maintaining remission [2-6]. However, a considerable number of
patients either fail to respond to TNF-a-antagonists (primary non-responders) or lose response
over time (secondary loss of response). Formation of anti-drug antibodies (ADAs) is an
important cause for secondary loss of response [7]. IFX trough levels (TLs) and ADAs can be
measured from patients’ serum samples by using commercial available immunoassays. These
measurements are valuable tools in optimizing IFX therapy [8-10]. Recently, ADA cross-
reactivity between originator IFX and CT-P13 has been described [11].
In June 2013, the European Medical Agency (EMA) accepted IFX biosimilar (CT-P13) for all
indications of the originator product [12]. For CD and UC, the indication was extrapolated from
studies showing efficacy of biosimilar IFX in ankylosing spondylitis and rheumatoid arthritis
[13,14]. This extrapolation of indication raised concern among national and international IBD
societies regarding the safety and interchangeability of biosimilars [15]. In IBD patients only
limited data were available of the efficacy and safety of CT-P13 until recently. First real-life
data of CT-P13 in induction therapy for IBD patients and switching from originator has recently
been published [16-25].
The aim of our study was to evaluate changes in TLs, ADA formation and disease activity after
switching from originator to biosimilar IFX during IBD maintenance therapy.
52. Patients and Methods
2.1. Switching programme design
All IBD patients receiving IFX (RemicadeTM, Janssen Biotech, Inc/ Schering-Plough, EU)
maintenance therapy at Helsinki University Hospital were switched to biosimilar IFX
(RemsimaTM, Celltrion Pharm, Inc., South Korea) in the beginning of year 2016. IFX TLs and
ADAs were measured before the last originator IFX infusion (baseline) and before the third
biosimilar IFX infusion (follow-up). Blood samples for measurements of haemoglobin,
leukocytes, platelets and serum C-reactive protein (CRP) were also taken at these time points.
Faecal calprotectin (FC), Partial Mayo Score (PMS) and Harvey Bradshaw index (HBI) were
used to assess clinical disease activity [26,27].
IFX TLs were measured with capture-ELISA (Promonitor EIA, Progenica) at United Medix
Laboratories (Helsinki, Finland) and the levels of ADAs were analyzed with fluid-phase
radioimmunoassay (Sanguin Laboratories, The Netherlands). IFX TLs below 0.03 mg/l and
ADAs below 12 AU/ml were considered non-detectable. Patients having an originator IFX TL
below or above the target level 3 – 7 mg/l [8] and needing dose adjustment were excluded from
paired analyses.
FC was measured in the routine clinical laboratory by a quantitative enzyme immunoassay
(PhiCal Test, Calpro AS, Oslo, Norway) and the values quoted as normal were <100 µg/g of
stool [28].
2.2. Statistical analyses
Laboratory values are presented as median and interquartile Range (IQR). Disease activity is
presented as mean and standard deviation (SD). Wilcoxon Signed-Rank test served as exploring
changes between related variables. For further analysis of TLs, we used the nonparametric two
6one-sided test of equivalence for paired samples [29]. Equivalence was established if the 95%
confidence interval (CI) of the median difference in the TLs before and after switching fell
within the equivalence boundaries. The boundaries were set to +/- the median absolute
deviation about the median of the baseline IFX TL of all patients, indicating that the change of
TL after switch for a patient tends to be smaller than the baseline TL difference between the
patients. Matplotlib version 1.5.1. was used for figure-drawing. Significance was set at 0.05.
2.3. Ethical considerations
The change of maintenance originator IFX to biosimilar IFX and measurements of TLs and
ADAs occurred as a part of the routine clinic work based on the hospital’s medical decisions.
The study was approved by the ethics committee of the Helsinki University Hospital (Dnro
32/13/03/01/2016) and research study permission was received from the Hospital District of
Helsinki and Uusimaa (HUS-170-2016-2).
3. Results
3.1. Patients and infliximab trough levels
Switching from maintenance originator IFX to biosimilar IFX occurred in 78 patients (38 CD,
37 UC and 3 IBD-unclassified [IBD-u]). Because of the small number of IBD-u patients, the
data of UC and IBD-u patients were pooled. During maintenance originator IFX therapy, 47 of
78 (60.5%) had a TL below (n=16) or above (n= 31) the target trough concentration 3 – 7 mg/l.
Based on these baseline IFX TLs and clinical evaluation, 14 (17.9%) patients underwent dose
adjustment (nine with a TL below 3 mg/l and five with a TL above 7 mg/l) and were excluded
from the paired concentration analyses. Two patients were excluded because of changes in the
infusion regime due to non-medical reasons.
Paired IFX TL and ADA measurements, clinical and laboratory data were available of 62
patients (32 CD, 30 CU/IBD-u) (Table 1). All UC patients had either left-sided colitis or
7extensive colitis. The majority of CD patients had an ileocolic involvement (20 patients,
62.5%). Of 32 CD patients, 20 (62.5%) and of 30 UC patients 24 (80%) used concomitant
immunomodulators. Median IFX infusion interval was 8 weeks (range 4 – 10 weeks).
During maintenance therapy with originator IFX, the median IFX TL of 62 patients was 5.5
mg/l (IQR 3.85 mg/l – 8.65 mg/l). The median follow-up IFX TL was 5.5 mg/l (IQR 3.15 mg/l
– 7.8 mg/l). The median TL difference was 0.45 mg/l. There was no statistically significant
change (p=0.05) in TLs before and after switching (Figure 1 and 2).
We also analysed the data separately for CD and UC. For CD patients, the median IFX TL was
5.75 mg/l (IQR 4.48 mg/l – 8.4 mg/l) before and 6.5 mg/l (IQR 3.98 mg/l – 8.35mg/l) after
switch and no statistical significant difference was detected (p=0.68). The median TL difference
in the CD subgroup was 0.4 mg/l (see Figure 3a). However, in UC/IBD-u patients the change
in median IFX TLs before and after switching was statistically significant: from median
baseline TL 5.2 mg/l (IQR 3.8 mg/l – 8.65 mg/l) to follow-up TL 4.25 mg/l (IQR 2.6 mg/l –
6.45 mg/l, p=0.019). The median TL difference was 0.9 mg/l (see Figure 3b).
When analysing these data further we noticed that the difference between baseline and follow-
up TL in UC patients was mainly due to four patients that had TL difference greater than 3.2
mg/l. One of them had an undetectable TL with measurable ADAs after switching (baseline
and follow-up TL 7.4 mg/l and < 0.03 mg/l, respectively, and ADA 35 AU/ml) and experienced
a clinical disease relapse. Another patient with a great TL difference (11 mg/l before and 3.1
mg/l after switch) discontinued azathioprine medication a few weeks before the measurement
of follow-up TL, which might at least partly explain the difference. For the other two patients,
there was no obvious reason for the TL difference. These three patients remained in clinical
remission.
83.2. Anti-drug antibodies
At baseline ADAs were detectable only in one of 78 (1.3%) patient with a titre of 18 AU/ml.
Because of an IFX dose adjustment that patient was excluded from final paired analysis, but in
follow-up after shortening of IFX interval the ADAs were undetectable.  After switching, one
patient on IFX monotherapy and one on a combination therapy with azathioprine developed
ADAs (titres12 AU/ml and 35 AU/ml, respectively).
3.3. Disease activity
Disease activity at baseline and follow-up is shown in Table 2. Mean HBI was 1.22 (SD 2.29)
before and 1.16 (2.22) after switching. Mean PMS was 1.2 (SD 1.76) before and 0.8 (SD 1.28)
after switching. The disease activity during switching neither in UC nor in CD showed
statistical difference (p=0.89 and p=0.07). In the whole study group, median FC concentration
was 69 µg/g (IQR 10 – 251 µg/g) before and 26 µg/g (IQR 13 – 180 µg/g) after switching
(p=0.78).  Rate of infusion reactions was low after switching (4 out of 156 infusions, 2.5%):
There was one reaction during biosimilar IFX infusion (throat sensation) and three potentially
infusion related adverse effects after the first or second biosimilar infusion (rash, headache and
nausea, fever and diarrhea). None of these effects resulted in discontinuation of the therapy.
4. Discussion
In this single-centre observational study all IBD patients receiving maintenance IFX therapy
were switched to biosimilar IFX without any effects on IBD activity. Switching caused no
statistically significant differences in IFX TLs in the whole IBD group or in CD subgroup. In
the UC subgroup, however, TLs were statistically significantly lower after switching.
9Since year 2013 EMA approval, evidence of biosimilar infliximab use in extrapolated
indications, such as IBD has accumulated. In this study where all IBD patients on maintenance
originator infliximab were switched to biosimilar one, we observed no differences in disease
activity, laboratory values, infusion reactions and adverse effects. Our findings are in line with
results from recently published studies [19-25]. Razanskaite and co-workers found no
significant differences between originator and CT-P13 in terms of drug persistence, side effects,
adverse effects, disease activity, or blood tests. TLs and ADAs did not show significant
difference before and after switch [19]. Smits and co-workers showed that switching to
biosimilar IFX led to a nonsignificant slight increase in median TL at week 16 (from 3.6 ug/ml
at week 0 to 4.2 ug/ml), but not at week 52 (3.6 ug/ml and 3.7 ug/ml). There was no effect on
disease activity [20,21]. Also in the study of Buer and co-workers disease activity, laboratory
values and IFX TL remained stable in a six months follow-up period after switching [23]. In
the large randomized NOR-SWITCH study no significant differences were observed one year
after switch in clinical activity indices, serum CRP, FC or TLs in UC patients. In CD patients,
changes in patient's and physician’s global assessment of disease activity showed some
improvement in those receiving originator IFX compared to those on biosimilar IFX [24].
Different from the NOR-SWITCH results, we detected significantly lower TLs after switching
in UC patients. Although this difference is statistically significant, the clinical relevance of this
finding remains unclear and should be interpreted with caution because of the rather low patient
number in the UC subgroup. We point out that no changes in disease clinical activity occurred
and a constantly low FC concentration in these patients suggested a stable remission after
switching. As the follow up time in our study was only 16 weeks we cannot make any further
statement about the behaviour of patients’ TLs and ADA development after that period. It is
known that the clearance of biologicals is influenced by various patient dependent factors like
weight, disease severity, concomitant medication, albumin, and other pharmacokinetic and
10
pharmacodynamic factors [30,31]. Furthermore, the use of a concomitant immunosuppressive
medication is a well-known factor that reduces the clearance of IFX, increases trough
concentrations and reduces the risk of ADA formation [32]. In current study, however, the use
of concomitant immunomodulators does not explain the observed differences in TLs in UC
patients, because the use of these medications was even higher in the UC than in the CD
subgroup. Another limitation of our study was a lack of a control group continuing on originator
IFX. Therefore, it remains unresolved whether the change in median TL in UC patients is due
to switching to the biosimilar IFX or due to other patient dependent or pharmacological factors.
It is unlikely that the difference in IFX TLs could be explained by the ELISA test used. It has
been shown in a recent real-life study, that the ELISA tests used for measuring originator IFX
TLs and ADAs are feasible also for biosimilar IFX measurements [33].
During maintenance IFX therapy over a half of the patients in our study had TLs either below
or above the suggested target level of 3 to 7 mg/l. This parallels the results of the TAXIT trial,
where 43.7 % of patients on maintenance IFX therapy had a TL between 3 and 7 mg/l [8]. In
that trial either reducing IFX dose in patients in clinical remission with TL over the target level
or dose escalation in those with a low TL was safe and feasible. In our study de-escalation in
clinically stable patients occurred less often that dose escalation. Recently published data
suggest that even higher target TL for infliximab than that used in the TAXIT trial should be
obtained especially in perianal CD: patients with ﬁstula healing had signiﬁcantly higher median
serum IFX levels (15.8 mg/l) than those with active ﬁstulas (4.4 mg/l) [34].
The amount of infusion related reactions and potential adverse effects was low in our study
(2.5% of infusions). No severe adverse effects were reported. All patients continued therapy
with the biosimilar IFX. Thus, in IBD patients being in stable remission, switching from
maintenance originator IFX therapy to biosimilar one seems to be safe.
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To conclude, in this study, TLs before and after switch did not differ significantly in CD
patients, but a statistically significant decrease in TLs in UC patients occurred. The clinical
relevance of this decrease remains unclear as we could not observe any changes in clinical
disease activity or faecal calprotectin. No safety concerns occurred during switching.
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TABLES:
Table 1: Patients Demographic and Baseline Characteristics
CD (n= 32) UC /IBD-u(n=30)
Gender: Male, n (%) 21(65.6) 14(46.7)
Age, years, median (IQR) 35 (28-45) 37 (31-43)
Age at diagnosis, years, median (IQR) 19 (16-25) 27 (18-35)
Duration of disease, years, median (IQR) 13 (9-24) 9 (5-13)
Smoking, n (%)
no
yes
former
19 (59.4)
8 (25)
5 (15.6)
25 (83.3)
1 (3.3)
4 (13.3)
Montreal classification (%)
A1, A2, A3
L1, L2, L3, L4
B1, B2, B3
Perianal disease
E2, E3
9, 22, 1 (28.1, 68.8, 3.1)
5, 7, 20, 5 (15.6, 21.9, 62.5, 15.6)
14, 10, 8 (43.8, 31.3, 25)
8, (25)
-
-
-
-
-
15 (50), 15 (50)
Time using IFX, days, median (IQR) 1544 (531-2072) 361 (216-957)
Concomitant medication n (%)
Azathioprine
6-Mercaptopurin
Methotrexate
Mesalamine
Corticosteroids
16 (50)
1 (3.1)
3 (9.4)
3 (9.4)
1 (3.1)
18 (60)
2 (6.7)
4 (13.3)
12 (40)
2 (6.7)
CD, Crohn’s Disease; UC, Ulcerative Colitis; IBD-U, IBD-unclassified
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Table 2: Disease activity
CD (n=32) UC /IBD-u (n=30)
Baseline after switch p-value Baseline after switch p-value
HBI, mean (SD) 1.22 (2.29) 1.16 (2.22) 0.89 - - -
PMS, mean (SD) - - - 1.2 (1.76) 0.8(1.28) 0.07
Calprotectin µg/g
median (IQR) 22 (10-189) 17 (5-312) 0.35 82 (9-270) 32 (20-169) 0.54
Haemoglobin g/l
median (IQR) 140 (131-150) 146 (133-152) 0.14 138 (124-150) 141 (123-148) 0.31
Leucocytes E9/l
median (IQR) 6.7 (6.1-7.8) 6.7 (6.2-7.8) 0.21 7.0 (5.0-7.9) 6.1 (5.0-7.5) 0.16
Platelets E9/l
median (IQR) 252 (227-298) 160 (224-309) 0.91 281 (242-315) 249 (220-312) 0.26
CRP mg/l
median (IQR) 3 (3-3) 3 (3-5) 0.875 3 (3-3) 3 (3-3) 0.577
CD, Crohn’s Disease; UC, Ulcerative Colitis; IBD-U, IBD-unclassified
HBI, Harvey-Bradshaw Index; PMS, Partial Mayo Score
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Figure legends:
Figure 1: Trough levels before (BASE IFX) and after (FU IFX) switching from originator to
biosimilar infliximab in Crohn’s disease (CD) patients. The dotted line presents the median
trough level.
Figure 2: Trough levels before (BASE IFX) and after (FU IFX) switching from originator to
biosimilar infliximab in ulcerative colitis (UC) patients. The dotted line presents the median
trough level.
Figure 3a & b:  Distribution of trough level differences before (BASE IFX) and after (FU
IFX) switching from originator infliximab (IFX) to biosimilar IFX in CD patients (a) and in
UC patients (b).
The median differences and its 95% confidence intervals (CI) are marked with a solid dot and
arrows. The difference is statistically significant (p < 0.05) if zero is not covered by the
interval between the arrows. Trough levels are considered equivalent if the interval between
the arrows does not cross the equivalence margins shown with dashed vertical lines.
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